INVO Fertility Announces 1-for-4 Reverse Stock Split

SARASOTA, Fla., Oct. 27, 2026 /CourierPR/ -- INVO Fertility, a healthcare company focused on establishing, acquiring, and operating fertility clinics and related businesses and technologies, is set to undergo a significant corporate restructuring. Effective pre-market opening on October 30, 2026, the company will implement a 1-for-4 reverse stock split, impacting its common stock trading on The Nasdaq Capital Market.

As part of this restructuring, the company’s common stock will trade on a post-split basis under the same trading symbol, “IVF.” The CUSIP number for the company’s common stock will change to 44984F872. The reverse stock split will result in every four shares of issued and outstanding common stock being exchanged for one share. Registered holders of record who would otherwise hold a fractional share will be rounded up to the next whole share. Beneficial holders holding shares in street name through a broker or nominee who would otherwise be entitled to receive a fractional share will receive a cash payment for such fractional interest, administered by the applicable broker or nominee in accordance with their standard procedures.

Following the effective time of the reverse stock split, INVO Fertility will have approximately 1,192,841 shares of common stock issued and outstanding. The company will also make a proportionate adjustment to its authorized shares of common stock, such that it will have 62,500,000 shares of authorized common stock after the effective time of the reverse stock split.

INVO Fertility, Inc. remains committed to expanding assisted reproductive technology (ART) care to patients in need. The company’s principal commercial strategy is focused on building, acquiring, and operating fertility clinics and related businesses and technologies. Currently, INVO Fertility operates four fertility clinics in the United States and continues to engage in the sale and distribution of its INVOcell technology solution into third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body.

The company’s forward-looking statements are subject to the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding the company’s expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions, are forward-looking statements. These statements involve risks, uncertainties, and contingencies, many of which are beyond the company’s control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements.